Skip to main content
SpringerLink
Log in

Amifostine protects a broad range of normal tissues from chemotherapy-and radiotherapy-associated toxicity

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999; 21(5): 367–87

    Article  PubMed  CAS  Google Scholar 

  2. Culy CR, Spencer CM. Amifostine. An update of its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001; 61(5): 641–84

    Article  PubMed  CAS  Google Scholar 

  3. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12

    PubMed  CAS  Google Scholar 

  4. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134–40

    Article  PubMed  CAS  Google Scholar 

  5. Anderson H, Mercer V, Thatcher N. A phase III randomised trial of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small cell lung cancer (NSCLC) [abstract]. 34th Proc Am Soc Clin Oncol 1998; 17: Los Angeles (CA), 465a

    Google Scholar 

  6. Gold MA, Walker JL, Berek JS, et al. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase II trial in patients with advanced gynecologic malignancies [abstract]. Gynecol Oncol 2000; 76: 279

    Google Scholar 

  7. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 3038–47

    PubMed  CAS  Google Scholar 

  8. Hartmann J, von Vangerow A, Fels LM, et al. A randomised trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84(3): 313–20

    Article  PubMed  CAS  Google Scholar 

  9. Patriarca F. Amifostine pretreatment for protection against melphalan + busulfan-induced toxicity in high-dose therapy for multiple myeloma patients [abstract no. 5034]. Blood 1999; 94 Suppl. I (Pt 2): 404b

    Google Scholar 

  10. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18(19): 3339–45

    PubMed  CAS  Google Scholar 

  11. Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer [abstract no. 18] Int J Radiat Oncol Biol Phys 1999; 45 Suppl. 3: 154

    Article  Google Scholar 

  12. Bennett CL, Golub R, Calhoun E, et al. Cost-utility assessment of amifostine in first-line therapy for ovarian cancer [abstract]. Int J Gynecol Cancer 1998; 8: 64–72

    Google Scholar 

  13. Alva Pharmaceuticals. Ethyol (amifostine) for injection product information. Available from URL: http://www.ethyol.com/pros/pi.htm [Accessed 2001 Aug 3]

  14. British National Formulary. No. 41 London: The Pharmaceutical Press, 2001 Mar

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amifostine protects a broad range of normal tissues from chemotherapy-and radiotherapy-associated toxicity. Drugs Ther. Perspect 17, 1–5 (2001). https://doi.org/10.2165/00042310-200117210-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117210-00001

Keywords

Search

Navigation